Research Site

Valdivia 5110683

4 studies enrolling now · 13 studies all time

What they study most

Acute Ischaemic Stroke, Cardiovascular Disease, Chronic Kidney Disease and Hypertension, Heart Failure and Impaired Kidney Function, Heterozygous Familial Hypercholesterolaemia, IgAN, Immunoglobulin A Nephropathy, Nonalcoholic Steatohepatitis, Respiratory Syncytial Virus, Respiratory Syncytial Virus Infections, Rheumatoid Arthritis, Systemic Lupus Erythematosus

Studies at this site

• A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure — Recruiting now
• A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event — Recruiting now
• Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function — Recruiting now
• A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis — Recruiting now
• Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus — Running, not enrolling
• A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH — Running, not enrolling
• A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event — Running, not enrolling
• A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure. — Running, not enrolling
• Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN) — Running, not enrolling
• A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis — Completed
• A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Preterm Infants. — Completed
• A Phase 1b/2a Randomized, Double-Blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants — Completed
• [SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES] — Completed